DGAM
NBIX icon

Desjardins Global Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Desjardins Global Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$57.1K Buy
433
+6
+1% +$691 0.01% 519
2023
Q3 		$48K Buy
+427
New +$45K 0.01% 538

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Desjardins Global Asset Management's NBIX Position: Q4 2023 in Review

Desjardins Global Asset Management increased its Neurocrine Biosciences (NBIX) stake by 1.4% in Q4 2023, buying an estimated $691 and bringing the position to 433 shares worth $57.1K. The position accounts for 0.01% of the portfolio, ranked #519.

Desjardins Global Asset Management first reported a position in NBIX in Q3 2023 and has held it in 2 quarters since. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • Desjardins Global Asset Management held 433 shares of Neurocrine Biosciences worth $57.1K as of Q4 2023.
  • Desjardins Global Asset Management bought 6 Neurocrine Biosciences shares in Q4 2023, an estimated $691.
  • Neurocrine Biosciences made up 0.01% of Desjardins Global Asset Management's portfolio in Q4 2023, its #519 holding.
  • Desjardins Global Asset Management first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 2 quarters since.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on Desjardins Global Asset Management's 13F filing for Q4 2023, filed 30 Jan 2024.